Abstract
Depression is a major cause of worldwide disability. Although its etiology is unclear, for over sixty years the study of its pathophysiology has focused mainly on serotonin (5-HT) and serotonergic neurotransmission. Generally, the study of the pathophysiological processes underpinning depression have led to the appreciation of its complexity, although such study continues to support the role of 5-HT in this disorder.
The aim of this review is to briefly summarize the available findings on 5-HT and depression, with a special focus on alterations in tryptophan (TRP) metabolism that can shift from 5-HT synthesis towards other, potentially neurotoxic, compounds, such as the tryptophan catabolite, quinolinic acid.
The evidence that the TRP shunt may be promoted by stress hormones and proinflammatory cytokines strongly supports the notion that depression should now be considered a systemic disorder that can be triggered by different factors that ultimately target the 5-HT system in vulnerable individuals. In addition, such intriguing findings suggest biochemical targets for novel treatment options in depression.
Keywords: Depression, serotonin, biological markers, tryptophan, tryptophan shunt, kynurenine.
Current Pharmaceutical Design
Title:Depression, Serotonin and Tryptophan
Volume: 22 Issue: 8
Author(s): Liliana Dell’Osso, Claudia Carmassi, Federico Mucci and Donatella Marazziti
Affiliation:
Keywords: Depression, serotonin, biological markers, tryptophan, tryptophan shunt, kynurenine.
Abstract: Depression is a major cause of worldwide disability. Although its etiology is unclear, for over sixty years the study of its pathophysiology has focused mainly on serotonin (5-HT) and serotonergic neurotransmission. Generally, the study of the pathophysiological processes underpinning depression have led to the appreciation of its complexity, although such study continues to support the role of 5-HT in this disorder.
The aim of this review is to briefly summarize the available findings on 5-HT and depression, with a special focus on alterations in tryptophan (TRP) metabolism that can shift from 5-HT synthesis towards other, potentially neurotoxic, compounds, such as the tryptophan catabolite, quinolinic acid.
The evidence that the TRP shunt may be promoted by stress hormones and proinflammatory cytokines strongly supports the notion that depression should now be considered a systemic disorder that can be triggered by different factors that ultimately target the 5-HT system in vulnerable individuals. In addition, such intriguing findings suggest biochemical targets for novel treatment options in depression.
Export Options
About this article
Cite this article as:
Dell’Osso Liliana, Carmassi Claudia, Mucci Federico and Marazziti Donatella, Depression, Serotonin and Tryptophan, Current Pharmaceutical Design 2016; 22 (8) . https://dx.doi.org/10.2174/1381612822666151214104826
DOI https://dx.doi.org/10.2174/1381612822666151214104826 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Promise of Cholesteryl Ester Transfer Protein (CETP) Inhibition in the Treatment of Cardiovascular Disease
Current Pharmaceutical Design Progress in the Development of Aminopeptidase N (APN/CD13) Inhibitors
Current Medicinal Chemistry - Anti-Cancer Agents Homocysteine-Lowering Treatment in Coronary Heart Disease
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Leptin and the Cardiovascular System: A Review
Recent Patents on Cardiovascular Drug Discovery Cardiovascular Complications of Obesity
Current Respiratory Medicine Reviews A Glance on the Role of Bacterial Siderophore from the Perspectives of Medical and Biotechnological Approaches
Current Drug Targets microRNAs in Cancer: Lessons from Melanoma
Current Pharmaceutical Design Cell Microencapsulation Implants into the Central Nervous System
Recent Patents on Nanomedicine Discussion on Pharmacogenetic Interaction in G6PD Deficiency and Methods to Identify Potential Hemolytic Drugs
Cardiovascular & Hematological Disorders-Drug Targets Design, Synthesis and Cytotoxicity of Chalcone Analogs Derived from 2-Phenylimino-3-phenylthiazolidin-4-one
Letters in Drug Design & Discovery Dealing with the Substance Abuse Epidemic and Infective Endocarditis:Clinical, Immunologic and Pathogenetic Aspects
Current Vascular Pharmacology Coronary CT Angiography in the Diagnosis of Coronary Artery Disease
Current Medical Imaging Ventilatory Abnormalities During Exercise in Heart Failure: A Mini Review
Current Respiratory Medicine Reviews Developments in Imaging Technologies Related to Hypertensive Cardiovascular Diseases
Current Pharmaceutical Design Inflammation-Mediating Proteases: Structure, Function in (Patho) Physiology and Inhibition
Protein & Peptide Letters Discovery and Pre-clinical Development of Antithrombotics from Hematophagous Invertebrates
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Clinical Vignettes: Integrated Care of Cancer Patients by Oncologists and Cardiologists
Current Cardiology Reviews Adverse Drug Reactions in a Pulmonary Teaching Hospital: Incidence, Pattern, Seriousness, and Preventability
Current Drug Safety Why and How We Should Treat Elderly Patients with Hypertension?
Current Vascular Pharmacology Gene Therapy Approaches in an Autoimmune Demyelinating Disease: Multiple Sclerosis
Current Gene Therapy